683 Capital Management’s Cellectis CLLS Stock Holding History

683 Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-352,638	Closed	-$2.86M	–	362
2021 Q4	$2.86M	Buy	352,638 +292,738	+489%	+$2.88M	0.11%	115
2021 Q3	$756K	Hold	59,900	–	–	0.03%	148
2021 Q2	$927K	Hold	59,900	–	–	0.03%	152
2021 Q1	$1.21M	Sell	59,900 -155,486	-72%	-$3.84M	0.06%	116
2020 Q4	$5.83M	Buy	215,386 +15,386	+8%	+$345K	0.28%	66
2020 Q3	$3.7M	Hold	200,000	–	–	0.27%	62
2020 Q2	$3.56M	Buy	+200,000	New	+$3.04M	0.28%	58

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's CLLS Position: Q1 2022 in Review

683 Capital Management sold out of Cellectis (CLLS) in Q1 2022, closing a stake of 352,638 shares — an estimated $2.86M sold.

683 Capital Management first reported a position in CLLS in Q2 2020 and held it in 7 quarters. The position peaked at $5.83M in Q4 2020. 51 funds tracked by Wall St. Rank hold CLLS as of Q1 2022.

683 Capital Management reported no remaining Cellectis position as of Q1 2022 after selling out during the quarter.
683 Capital Management sold 352,638 Cellectis shares in Q1 2022, an estimated $2.86M.
683 Capital Management first reported a position in Cellectis in Q2 2020 and held it in 7 quarters.
683 Capital Management's Cellectis position peaked at $5.83M in Q4 2020.
51 funds tracked by Wall St. Rank held Cellectis as of Q1 2022.

Based on 683 Capital Management's 13F filing for Q1 2022, filed 16 May 2022.